Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 1, 1999, Pages 12-18

  Kurata, Noriaki ^a   Kuwabara, Takashi ^a   Tanii, Hiromi ^a   Fuse, Eiichi ^a   Akiyama, Tadakazu ^a   Akinaga, Shiro ^a   Kobayashi, Hiroyuki ^a   Yamaguchi, Ken ^b   Kobayashi, Satoshi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

7 Hydroxystaurosporine (UCN 01); HPLC; Pharmacodynamics; Pharmacokinetics

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CISPLATIN; MITOMYCIN; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOG; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG STRUCTURE; EXPERIMENTAL NEOPLASM; INTRAVENOUS DRUG ADMINISTRATION; LIVER CLEARANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; STAUROSPORINE; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033031444     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050939     Document Type: Article

References (23)

1. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M (1991) Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51: 4888
2. Akinaga S, Nomura K, Gomi K, Okabe M (1993) Diverse effects of indolocarbazole compounds on the cell cycle progression of ras-transformed rat fibroblast cells. J Antibiot 46: 1767
3. Akinaga S, Nomura K, Gomi K, Okabe M (1993) Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32: 183
4. Akinaga S, Nomura K, Gomi K, Okabe M (1993) Synergistic antitumor effect of UCN-01, a protein kinase (C) inhibitor, combined with various anti-cancer agents. Proc Am Assoc Cancer Res 33: 3072
5. Akinaga S, Nomura K, Gomi K, Okabe M (1994) Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol 33: 273
6. Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S (1997) G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/ Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 57: 1495
7. Bunch RT, Eastman A (1996) Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 2: 791
8. Ceran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological system. Cancer Chemother Rep 3 (Part 3): 1
9. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73
10. Fuse E, Kobayashi S, Inaba M, Suzuki H, Sugiyama Y (1994) Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity. J Natl Cancer Inst 86: 989
11. 1-acid glycoprotein. Cancer Res 58: 3248
12. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics. Marcel Dekker, New York, p 409
13. Kawakami K, Futami H, Takahara J, Yamaguchi K (1996) UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 219: 778
14. Kurata N, Kuramitsu T, Tanii H, Fuse E, Kuwabara T, Kobayashi H, Kobayashi S (1998) Development of a highly sensitive high-performance liquid Chromatographic method for measuring an anticancer drug, UCN-01, in human plasma or urine. J Chromatogr B 708: 223
15. Lush RM, Senderowicz A, Figg WD, Headlee D, Inoue K, Sausville EA (1997) Surprising pharmacokinetics of UCN-01 in patients with refractory neoplasms may be due to high degree of protein binding. Proc Am Assoc Cancer Res 38: 600
16. Pollack IF, Kawecki S, Lazo JS (1996) Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor. J Neurosurg 84: 1024
17. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ (1993) Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53: 2081
18. Shimoyama M (1975) Cytocidal action of anticancer agents: evaluation of the sensitivity of cultured animal and human cancer cell lines. In: Ito Y, Dutcher RM (eds) Comparative leukemia research 1973. University of Tokyo Press, Tokyo Basel, p 711
19. Skipper HE, Schabel FM Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW (1970) Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54 (Part 1): 431
20. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakano H (1987) UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J Antibiot 40: 1782
21. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM (1996) UCN-01; a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88: 956
22. Watari N, Benet LZ (1989) Determination of mean input time, mean residence time, and steady-state volume of distribution with multiple drug inputs. J. Pharmacokinet Biopharm 17: 593
23. Yokota M, Iga T, Awazu S, Hanano M (1976) Simple method of hepatic venous blood sampling in the rat. J Appl Physiol 41: 439